Astatine-211 based radionuclide therapy: Current clinical trial landscape
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2022.1076210
Abstract: Astatine-211 (211At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize… read more here.
Keywords: 211 based; therapy current; based radionuclide; current clinical ... See more keywords